NextDocs Sets Industry Standard for Scalability of Regulated Compliance Solutions

NextDocs, a leading provider of regulated content management and compliance solutions for the life sciences industry, today provided updated benchmark data on the scalability of its NextDocs 6 solution – and discussed the details of some of the company’s large-scale implementations.

NextDocs reported that its solutions have now been deployed at more than 100 life sciences companies, including five of the top 10 largest global pharmaceutical companies and two of the largest CROs. This record, particularly at the world’s largest pharmaceutical companies and CROs, demonstrates scalability and performance in some of the most demanding operational environments. As an example of production deployments of NextDocs 6, the company cited its recent go-live at a Fortune 100healthcare company with more than $40 billion in annual revenues and 30,000 employees.

“Global life sciences companies need their regulated content and compliance management systems to be highly scalable, highly reliable and high performing. NextDocs made significant investments to meet the technical and operational demands of these companies,” said Zikria Syed, Chief Executive Officer of NextDocs. “By releasing our scalability benchmark data publicly, it not only validates the capabilities of the NextDocs 6 solution, but also gives our customers the highest confidence that our solutions will meet and exceed their most stringent requirements.”

NextDocs also publicly released a report, SOP Scalability in Life Sciences, providing detailed benchmarks on the scalability and performance of its regulated compliance solutions. The company is publishing the benchmark data to establish a new set of industry standards on which life sciences companies can rely when evaluating these mission critical systems.

Scalability and performance are critical to the success of enterprise technology deployments. However, when it comes to regulated compliance systems, there has been little comparative information publicly available. Thus, companies are often in the dark on what constitutes best-in-class capabilities. By releasing the industry’s first scalability and performance benchmarks for regulated compliance solutions, NextDocs hopes to educate companies on system performance and elevate standards in the industry.

The benchmark report, SOP Scalability in Life Sciences, goes beyond previously published reports. Those older tests focused on document read and write, browsing and downloading performance – actions not specific to compliance scenarios. The newly released report includes data for compliance-specific actions including PDF rendering, workflows, approvals and content indexing – providing more detailed benchmarking to the industry.

The data is derived from lab testing of real-world deployments and real-world compliance scenarios. NextDocs partnered with Microsoft to conduct the testing in the Microsoft Life Sciences Lab and utilized only customer-provided scenarios. The NextDocs platform was successfully tested at 75,000 users with 200 concurrent contributors and 1,000 concurrent readers accessing a site collection containing over 550,000 documents. The updated SOP Scalability in Life Sciences report is available for download at

NextDocs 6 added expanded capabilities to meet the demands of the highly global, mobile and collaborative life sciences operating environment. Those NextDocs 6 enhancements are designed to meet the business needs of both mature companies with large and highly developed online regulated content management processes, as well as emerging, high-growth companies that aspire to more automated, scalable and compliant processes.

“NextDocs 6, combined with Microsoft SharePoint, is a highly scalable, performance controlled document management platform, tested and proven for large-scale environments,” said Zikria Syed. “And NextDocs will continue to publish public benchmark data to back up that claim and push the envelope in the industry. We think our customers and the industry will benefit immensely from greater transparency and more comprehensive benchmark data. ”